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Store-operated channeld cancer-related cause of death. Nowadays, the aim of treatments is to decrease
the effects of androgens on this organ. Unfortunately, over time, patients develop an androgen-independent
cancer with a fatal outcome. The main features of late stage prostate cancer are an increased cell proliferation
and apoptosis resistance. It is well known that calcium (Ca2+), a ubiquitous secondary messenger, is involved
in several processes such as apoptosis and proliferation. In this mini review, we will focus on the changes in
Ca2+ homeostasis of prostate cancer epithelial cells during prostate cancer evolution.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer is one of the leading threats to men's health. Its
early stage depends on androgens for growth and survival, and at this
time, androgen ablation therapy may be effective in tumour regres-
sion. However, in the late androgen-independent stage there is
currently no successful therapy. It is, therefore, vital to understand
what drives the progression of prostate cancer to androgen indepen-
dence. The latter is associated with the appearance of new cell
phenotypes, characterised by apoptosis inhibition and aberrant cell
proliferation. Deregulated cell differentiation and proliferation,
together with the suppression of apoptosis provides the conditions
for abnormal tissue growth, which ultimately can turn into uncon-
trolled expansion and invasion (Fig. 1).
The role of Ca2+ is well established in the majority of the cell-
signalling pathways involved in carcinogenesis (see [1] for a review).
Ca2+ homeostasis, the consequences of Ca2+ signalling, is a steady
state between Ca2+ inﬂux, efﬂux, and storage. From a physiological
point of view, Ca2+ signalling is involved in the manifestation of cell
phenotypes, proliferation, differentiation, apoptosis, and in cellular
activities such as contraction, secretion or cell excitability. Thus, each
cellular phenotype, whether normal or pathological, is characterised
by a particular ‘Ca2+ Signature’ reﬂecting its kinetics, amplitude and
subcellular localization of the Ca2+ signals (see [2] for a review). Theie Cellulaire, INSERM U800,
Tel.: +33 3 20 43 68 38; fax:
. Flourakis).
ll rights reserved.Ca2+ signals derive either from (i) internal stores, usually the
endoplasmic reticulum (ER), after stimulation by intracellular
messengers such as inositol 1,4,5 trisphosphate (IP3) or cyclic ADP-
ribose [3], or from (ii) the external medium. In the case of the latter,
there are many different plasma membrane channels that control Ca2
+ entry in basal conditions, or in response to stimuli such as extra- or
intracellular agonists, or after the depletion of internal stores. Indeed,
rapid and highly localised Ca2+ signals regulate fast physiological
responses such as secretion and contraction, whereas global Ca2+
transient or intracellular Ca2+ waves control slower responses such as
mitosis and fertilization. For instance, cytosolic Ca2+ oscillations
stimulate cell proliferation via activation of the Ca2+-dependent
transcription factor, NFAT (Nuclear Factor of Activated T cells) [4], and
a sustained elevation in cytosolic Ca2+ concentration induces
apoptosis of cancer cells [5] (Fig. 2).
Calcium-permeable channels are potential candidates for partici-
pating in Ca2+ homeostasis into prostate cancer cells. One transient
receptor potential superfamily (TRP) of cation channels, which
includes a remarkable spectrum of channels mediating a variety of
sensory and receptor-induced signals, is of particular interest. The TRP
channels are classiﬁed in six different families: TRP-C (Canonical),—V
(Vanilloid), —M (Melastatin), —ML (Mucolipin), —P (Polycystin) and
—A (Ankyrin transmembrane protein). These channels are mainly
expressed in the plasma membrane (e.g. TRPV6) but could be also
localized in the ER membrane (e.g. TRPM8) where they can enhance
proliferation and/or aberrant differentiation.
In this mini review, we will describe the changes in Ca2+
homeostasis during prostate cancer evolution. Since the problem of
Ca2+ homeostasis in cancer cells is too vast, even in relation to
Fig. 1. Scheme summarizing prostate cancerogenesis and prostate cancer evolution after androgen deprivation therapy (AEC: apical epithelial cells, BEC: basal epithelial cells, SMC:
smooth muscle cells, NEC: neuroendocrine cells).
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ion channels in prostate cancer epithelial cells and their involvement
in prostate carcinogenesis), we will limit ourselves to three speciﬁc
changes: (i) the regulation of the basal Ca2+ entry by TRPV6, (ii) the
ER store depletion via TRPM8 and (iii) the store operated calcium
entry activated upon store depletion.
1.1. TRPV6: basal Ca2+ entry and prostate cancer cells proliferation
Based on a growing number of studies, TRP (transient receptor
potential) cationic channels appear to be key players in Ca2+Fig. 2. Spatial-temporal regulation of Ca2+ signalling. All Ca2+ signals are a combination of fo
for metabolism regulation, nucleus for transcription…) duration (from microseconds for ex
apoptosis) and amplitude (from small for proliferation to high for apoptosis). For exam
translocation, a sustained elevation of mitochondrial Ca2+ concentration could lead to apop
seconds, H: hours).homeostasis and cell physiopathology. Several members of the TRP
family appear to play an important role in prostate cancerogenesis;
furthermore, some of them have been suggested as prognostic
markers for prostate cancer, with particular use in differential
diagnosis [6].
In recent years, TRPV6 (TRP, Vanilloid member 6), a highly Ca2+-
selective channel, has emerged as a promising prognosis marker.
TRPV6 is strongly expressed in advanced prostate cancer prostate
cancer and signiﬁcantly correlates with the Gleason N7 grading,
making it a strong marker of tumour progression and subsequent
invasion into healthy tissues [7–9]. Indeed, TRPV6 expression isur parameters: subcellular localization (plasma–membrane for secretion, mitochondria
ocytosis to hours for fertilization), frequency (from slow for secretion to repetitive for
ple, if a cytoplasmic Ca2+ oscillation activates proliferation through NFAT nuclear
tosis. (Black dots: Ca2+, N: nuclear, ER: endoplasmic reticulum, M: mitochondria, Sec:
Table 1
Recently identiﬁed ion channels in prostate cancer epithelial cells and their involvement
in prostate carcinogenesis
Channels Localization Function Evolution during prostate
cancer progression
TRPC1 PM Inhibition of proliferation
and/or apoptosis induction
=
TRPC4 PM Inhibition of proliferation
and/or apoptosis induction
=
TRPC6 PM Stimulated proliferation ?
TRPV6 PM Basal proliferation ↗
ERTRPM8 ER ?: Proliferation =
PMTRPM8 PM ?: Secretion ↘
Cav3.2 PM Secretion ↗
SOC (Orail?) PM Apoptosis ?
(PM: plasma membrane, ER: endoplasmic reticulum, ↗ increase, ↘ decrease, = no
change, ?:unknown).
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prostate tissue TRPV6 expression is barely detectable and increases
with prostate cancer evolution, and the degree of metastasis. Previous
studies have shown that TRPV6 is involved in highly Ca2+-selective
currents in prostate cells, and that it is tightly regulated by
intracellular Ca2+ concentrations ([Ca2+]i) [10–12]. However, the
precise role of Ca2+ entry via TRPV6 in prostate physiopathology has
been elusive over the past years. A recent study by Prevarskaya's
research team reported that Ca2+ entry via TRPV6 directly controlled
proliferation after NFAT nuclear translocation in prostate cancer cells.
Moreover, in view of the strong correlation between TRPV6 expression
and the Gleason tumour grade in prostate cancer, TRPV6 expression
and activity are increased in late prostate cancer stages, thus
promoting the proliferation of prostate cancer cells [13].
1.2. TRPM8: store depletion or Ca2+ entry?
As for TRPV6, another member of the TRP channel family has
emerged as a promising prognosis marker and putative therapeutic
target for prostate cancer: TRPM8 (TRP melastatin member 8).
It is interesting to note that TRPM8 was originally cloned from
the prostate [14], recent studies have ﬁrmly established its function
as a cold receptor in sensory neurons [15], where it has been func-
tionally characterised as a plasma membrane (PM) cationic channel
involved in cold-evoked excitation. However, the features of the
classical plasma membrane TRPM8 (PMTRPM8) have not yet been
ﬁrmly established in prostate cells. While many hypotheses have
been put forward, the prostate-speciﬁc function of TRPM8 and the
role of Ca2+/Na+ inﬂow that it carries in prostate physiology and
carcinogenesis remain unknown. Indeed, two recent studies [6,16]
functionally characterised the TRPM8 channel in the human prostate
cancer Lymph Node Carcinoma of the Prostate (LNCaP) cell line. In
these cells TRPM8 is highly expressed, but is most exclusively
localised in the ER membrane, where it acts as an ER Ca2+ release
channel that supports the androgen-dependent component of store-
operated Ca2+ entry (SOCE). However, PMTRPM8 is not functional in
LNCaP cells.
A recent study by Prevarskaya's team has shown that TRPM8
localization and activity are regulated depending on the differentia-
tion and oncogenic status of prostate cancer cells [17]: only highly
differentiated prostate cancer cells expressed functional PMTRPM8
channels. More importantly, prostate cancer cells obtained from in
situ prostate cancer biopsies were characterised by PMTRPM8-
mediated current density that was signiﬁcantly stronger than that of
normal prostate or benign prostate hyperplasia cells. This PMTRPM8
activity was abolished in dedifferentiated prostate cancer cells that
had lost their luminal secretory phenotype. In contrast, ERTRPM8
remained functional regardless of the differentiation status of prostate
cells. This differential regulation of TRPM8 activity can be explained bythe complex regulation of ERTRPM8 and PMTRPM8 isoforms by the
androgen receptor (see Gkika et al. [17] for more details, in this issue).
Therefore, these data suggest that PMTRPM8 and ERTRPM8 may
determine speciﬁc, oncogenic status-dependent Ca2+ signatures
required for the progression of Ca2+-dependent processes that are
critical for carcinogenesis, such as proliferation [4,18,19] and apoptosis
[5,20]. Proliferation mostly relies on cytosolic Ca2+ signalling
involving short, repeated Ca2+ entry mechanisms [4,21]. Thus,
PMTRPM8 could be important for the Ca2+ signalling involved in
proliferation. Moreover, store depletion and SOCE were previously
shown to be critical in promoting growth arrest and apoptosis of
prostate cancer epithelial cells [22,23]. Indeed, reduced basal ﬁlling of
intracellular Ca2+ stores is also the hallmark of the apoptosis-resistant
cell phenotypes characteristic of advanced prostate cancer [5,20,22].
Thus, as ERTRPM8 is a molecular entity capable of inﬂuencing the
ﬁlling of ER stores, its activitymay be considered a substantial factor in
controlling the growth of advanced prostate cancer metastatic cells. In
light of the recent demonstration of the role of TRPM8 in LNCaP cell
survival [6], any shift in the balance between classical PMTRPM8 and
the ERTRPM8 isoform expression may modify the Ca2+ signature,
thereby increasing the potential for either proliferation or apoptosis.
Therefore, TRPM8 may be an attractive target for therapeutic
interventions: speciﬁc inhibition of either ERTRPM8 or PMTRPM8
activity should be considered, depending on the stage and androgen
sensitivity of the targeted prostate cancer.
1.3. SOCE and prostate cancer cell apoptosis
In prostate cancer epithelial cells, as in other non-excitable cell
types, Ca2+ entry from extracellular space is mainly supported by the
‘capacitative Ca2+ entry’ (CCE) mechanism, also known as SOCE (see
[24,25] for reviews). Thismechanism is capable of monitoring ER Ca2+
ﬁlling, enabling inﬂux only when the ER content is signiﬁcantly
decreased. It is mediated via specialised plasma membrane store-
operated Ca2+-permeable channels (SOC). The common physiological
trigger for the activation of these channels is an IP3-induced Ca2+
release from the ER in response to the stimulation of surface receptors
coupled to the phospholipase C-(PLC)-catalyzed inositol phospholipid
breakdown signalling pathway.
Alterations in Ca2+ homeostasis and in SOC activity seem to play
a major role in the establishment of an androgen-independent
apoptosis-resistant phenotype of prostate cancer. Indeed, the major
features of Ca2+ homeostasis in androgen-independent apoptosis-
resistant prostate cancer cells (such as LNCaP cells stably transfected
with Bcl-2 and androgen-deprived differentiated LNCaP cells)
compared to the wild-type androgen-dependent LNCaP cells are:
(i) reduced basal Ca2+ ﬁlling of the ER pool, and (ii) reduced store-
operated Ca2+ entry. [5,20] These changes were accompanied by an
increased resistance to thapsigargin- and Tumor Necrosis Factor
(TNF) α-induced apoptosis with a clear shift toward the higher
importance of Ca2+ inﬂux versus ER store depletion in apoptosis
induction compared to the wild-type androgen-dependent LNCaP
cells. Therefore, the identiﬁcation of the molecular nature of SOC and
the mechanisms of their activation/regulation are of great impor-
tance for understanding what drives prostate cancer to androgen-
independence. Years of frustration have marked the quest for the
molecular basis of SOC and for molecules underlying the process of
CCE. During this query, TRP channels were attractive candidates
involved in SOC formation [12,26]. Our study, conducted on
androgen-dependent LNCaP cells has suggested the involvement of
the TRPCs members (Canonical) TRPC1 and TRPC4 in prostate
endogenous SOC. However, the expression pattern of TRPC1 and
TRPC4 was not modiﬁed after an androgen-deprived differentiation
of prostate cancer epithelial cells.
Despite an intense study, the molecular characterization of SOCs
and the activation process for store-operated Ca2+ entry remained
Fig. 3. Scheme summarizing the changes in Ca2+ homeostasis in epithelial cells of late prostate cancer stages. The main features of late stage prostate cancer are (i) an increase in cell
proliferation which could be due to TRPV6 expression enhancement and (ii) a decrease in the apoptosis rate due to the decrease in the SOC entry (probably via Orai1 activation).
Moreover, the androgen deprived differentiation also induces an increase in the expression of Ca v vv3.2 isoform of T-type Ca2+ channel, this in turn enhances the secretion of
mitogenic factors which stimulate proliferation of surrounding cells via a receptor activated Ca2+ entry (probably TRPC6).
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teams determined that the Stromal Interaction Molecule 1 (STIM1) is
required for SOC activation [27,28]. In these studies, knocking down
the gene for STIM1 signiﬁcantly decreases SOC entry. STIM1 is a
77 kDa type 1 membrane protein located in the ER membrane and it
is likely that it is the ER Ca2+ sensor, redistributed after store
depletion into a localised region of the ER membrane, or punctae
close to the plasma membrane [27]. Nonetheless, while STIM1 itself
senses the store depletion and is involved in the SOCE pathway, the
SOC channel remains unknown. In recent years, a combination of
studies converged onto the identiﬁcation of a plasma membrane
protein named Orai1, or CRACM1. Orai1/CRACM1 is a widely
expressed 33 kDa plasma membrane protein with 4 trans-membrane
domains and with no sequence homology to other ion channels
[29–31]. The simple model for SOCE activation consists of STIM1
aggregation within punctae following store depletion. In this close
ER/plasma–membrane region, the cytoplasmic C-terminus of STIM1
interacts with the Orai1 protein, activating Ca2+ entry through the
latter (see [32] for a review).
STIM1 and Orai1 mediate CRAC currents and SOCE in a large
variety of cells and are involved in a wide range of cell functions such
as endothelial cells proliferation [33], lymphocyte proliferation [34],
mast cells activation [35], as well as skeletal muscle development and
a contractile function [36]. In particular, in the light of the SOC pivotal
role in the apoptosis resistance of prostate cancer, Orai1 and STIM1
have never previously been studied in prostate cancer cells and
further studies have yet to be performed.
1.4. Perspectives and conclusion
Fig. 3 presents a summary of the various channels involved in the
Ca2+ homeostasis, and which are deregulated during late stage
prostate cancer. The main features of this stage are (i) an increased
proliferation due to an increase in TRPV6 expression/activity, as well
as other channels such as TRPC6 and the voltage gated Ca2+ channel
(CaV 3.2); (ii) the emergence of apoptosis resistance due to a decrease
in SOCE (Fig. 3). However, further studies are needed, especially in
order to understand the involvement of Orai/STIM1 in CCE in the
prostate. Moreover, these channels are only studied in freshly isolated
cells and in prostate cancer cells lines. Hence, some in-vivo models
need to be used in order to better characterise the role of these
channels in prostate.Acknowledgment
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